

Combined transcatheter treatment of severe mitral regurgitation and secundum atrial septal defect in an inoperable patient: a case report

Fabian Barbieri ^{1*}, Ulf Landmesser ^{1,2,3}, Mario Kasner^{1†}, and Markus Reinthaler^{1,4†}

¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Cardiology, Hindenburgdamm 30, 12203 Berlin, Germany; ²DZHK (German Centre for Cardiovascular Research), Partner site Berlin, Potsdamer Straße 58, 10785 Berlin, Germany; ³Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany; and ⁴Institute of Active Polymers and Berlin-Brandenburg Center for Regenerative Therapies, Helmholtz-Zentrum Hereon, Kantstraße 55, 14513 Teltow, Germany

Received 13 June 2021; first decision 15 July 2021; accepted 15 November 2021; online publish-ahead-of-print 4 December 2021

Background

Chronic mitral regurgitation (MR) is one of the most common valvular heart diseases and is associated with poor outcomes. Although other structural diseases are regularly seen in such patients, concomitant atrial septal defects (ASDs) remain a rarity in the elderly.

Case summary

We report a case of an 82-year-old woman with progressive right-sided heart failure (HF) due to MR and an ASD of secundum type, despite optimal medical therapy. Combined transcatheter mitral valve repair (MVR) by utilizing a separate transseptal puncture and ASD closure was performed resulting in amelioration of symptoms.

Discussion

Procedural planning for simultaneous transcatheter therapies of coupled structural heart disease entities remains complex. Our case illustrates feasibility of percutaneous edge-to-edge MVR and consecutive closure of a large secundum ASD. Different options of accessing the left atrium should be discussed on an individual basis, while additional ASD closure may be beneficial in terms of right ventricular function and symptoms of right HF.

Keywords

Mitral regurgitation • Atrial septal defect • Atrial septal defect closure • Mitral valve repair • MitraClip • Case report • Transcatheter • Transcatheter therapeutics • Right heart failure

ESC Curriculum

2.2 Echocardiography • 4.3 Mitral regurgitation • 9.7 Adult congenital heart disease • 4.5 Tricuspid regurgitation • 4.9 Multivalvular disease

Learning points

- Transcatheter mitral valve repair (MVR) is feasible, despite presence of a large secundum type atrial septal defect (ASD). A transseptal puncture located in a posterior direction of the preformed ASD might be useful for left atrial access and should be discussed on an individual basis.
- Combined MVR and ASD closure may be associated with favourable clinical outcome in patients with right-sided heart failure due to pre- and afterload reduction of the right ventricle.

* Corresponding author. Tel: +49 30 450 613695, Email: fabian.barbieri@charite.de

† The last two authors contributed equally to this work.

Handling Editor: Dimitrios A. Vrachatis

Peer-reviewers: Mohammed Al-Hijji and Callum Little

Compliance Editor: Hibba Kurdi

Supplementary Material Editor: Elhosseyn Guella

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com




Figure 1 Colour Doppler images of preprocedural transoesophageal echocardiography showing severe mitral regurgitation in four-chamber (A) and two-chamber view (B) with systolic reversal of pulmonary vein flow (C). Furthermore, significance of left-to-right shunt via an atrial septal defect is displayed (D). LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.

At the first post-procedural day, the patient was transferred to the ward and discharged 6 days after the procedure.

Two weeks later, she returned for short-term ambulatory follow-up showing further amelioration of symptoms, no recurrence of ascites, and continuously regressing peripheral oedema. Furthermore, confirmation of trace MR with improvements in TAPSE (19 mm) and TR [EROA: 0.5 cm² (cut-off for severe TR: ≥0.4 cm²); VC: 12 mm (severe TR: ≥7 mm); regurgitation volume: 43 mL (severe TR: ≥45 mL)] were observed in TTE.

Discussion

Transcatheter MVR is a continuously evolving form of therapy for MR, which allows treatment of patients deemed as high risk or inoperable.¹⁻³ Although transcatheter MVR has become a standard of therapy in most tertiary hospitals, MR may also occur in combination with other structural diseases increasing the complexity of procedural planning. Generally, the presence of a secundum ASD is very tempting to be used for left atrial access as the preformed defect may easily be passed with the guiding catheter, but impaired manoeuvrability and lack of stability of the clip delivery system (CDS) may

complicate the procedure. In terms of manoeuvrability, the proximity of the line of coaptation to the ASD ostium causes suboptimal angulation of the CDS. This is especially of importance in primary MR due to prolapse or flail leaflet, as the line of coaptation is usually located in or above the plane of the mitral annulus.⁴ A similar situation was found in our patient, who presented with left atrial functional MR and coaptation line close to the annular plane. We therefore performed a transseptal puncture posterior to the ASD, which improved the deliverability of the devices due to a higher position of the CDS, besides the already mentioned optimization in stability compared to a free access through the ASD. However, transseptal puncture may not always be possible due to differences in anatomy of the defect. Fixation of the transseptal guide, for example by using a snare from the right jugular vein to grasp the CDS, might improve stability.

Overall, it remains debatable, which interventions were necessary for treatment of our patient. TR was interpreted as an expression of right-sided pressure and volume overload. Therefore, the aim of chosen therapy was to offer best possible RV relief by reducing afterload via MVR and preload via ASD closure.^{5,6} Although treatment of TR was initially deferred, it remained as option for supportive therapy in case of persisting HF symptoms. There are also certain situations in which ASD closure should be deferred. In patients with ongoing left







Figure 2 Transseptal puncture guided by multi-plane transesophageal echocardiography (A). Clip delivery system introduced into the left atrium via a separate transseptal puncture posterior to the immanent atrial septal defect (B). AV, aortic valve; LA, left atrium; MV, mitral valve; RA, right atrium; *, atrial septal defect; arrowheads, transseptal puncture stiletto (A) and clip delivery system (B).



Video 1 Multi-plane view showing implantation of the second MitraClip.



Video 2 Multi-plane view showing implantation of the Amplatzer occluder.



Video 3 Three-dimensional reconstruction showing final results after implantation of two clips significant reduction of mitral regurgitation and elimination of left-to-right shunt.

ventricular disease, the benefit of shunt elimination always needs to be weighed against potential harm because of increase in left ventricular filling pressure. Furthermore, ASD closure is contraindicated in Eisenmenger syndrome and severe pulmonary hypertension (≥ 5 WU), despite pharmacological treatment. Repetition of right-heart catheterization might be considered after MVR, whenever there is doubt about benefits of ASD closure.⁵

This case presentation illustrates feasibility of transcatheter MVR in patient with a large secundum ASD. Different options of accessing the left atrium should be discussed on an individual basis. Additional ASD closure may be beneficial in terms of RV function and symptoms of right HF.




Figure 3 Multi-plane colour Doppler images (A) and three-dimensional reconstruction with colour Doppler (B) after deployment of two MitraClips showing significant reduction of mitral regurgitation. Systolic pulmonary vein flow reversal was eliminated (C), while colour Doppler images illustrated persistence of significant left-to-right shunt via the atrial septal defect (D). AO, aorta; LA, left atrium; LV, left ventricle; LVOT, left ventricular outflow tract; RA, right atrium.




Figure 4 Multi-plane view with three-dimensional reconstruction showing the pre-existing and the artificial atrial septal defect (A), its sizing with balloon (B) and after deployment of an Amplatzer occluder (C, D). AO, aorta; LA, left atrium; MV, mitral valve; RA, right atrium; SVC, superior vena cava; *, atrial septal defect; §, artificial atrial septal defect; arrowheads, sizing balloon (B) and Amplatzer occluder (C, D).

Lead author biography



Fabian Barbieri graduated at the Medical University of Innsbruck (Austria), where he has also started to work as resident in 2018 and finished his PhD thesis. He continued his career at the Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin (Germany) in 2021.

Supplementary material

[Supplementary material](#) is available at *European Heart Journal - Case Reports* online.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as [Supplementary data](#).

Consent: The authors confirm that written consent for submission and publication of this case report including images and asso-

ciated text has been obtained from the patient in line with COPE guidance.

Conflict of interest: F.B. received grant support from Abbott Laboratories and Boston Scientific as well as consulting fees from Boston Scientific. U.L. reports personal fees from Abbott Laboratories, Biotronik and Boston Scientific.

Funding: We acknowledge support from the German Research Foundation (DFG) and the Open Access Publication Fund of Charité – Universitätsmedizin Berlin.

References

1. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS et al. Percutaneous repair or surgery for mitral regurgitation. *N Engl J Med* 2011;**364**:1395–1406.
2. Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. *J Am Coll Cardiol* 2015;**66**:2844–2854.
3. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017;**38**:2739–2791.
4. Mintz GS, Kotler MN, Segal BL, Parry WR. Two-dimensional echocardiographic recognition of ruptured chordae tendineae. *Circulation* 1978;**57**:244–250.
5. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP et al. 2020 ESC guidelines for the management of adult congenital heart disease. *Eur Heart J* 2021;**42**:563–645.
6. Kottenberg E, Dumont M, Frey UH, Heine T, Plicht B, Kahlert P et al. The minimally invasive MitraClip procedure for mitral regurgitation under general anaesthesia: immediate effects on the pulmonary circulation and right ventricular function. *Anaesthesia* 2014;**69**:860–867.